- Price
- $41.91
- Day
- +0.02%
- Mkt Cap
- $4.67B
- 52W Range
- $33.03 – $60.63
- Volume
- 2.90M
- Beta
- 1.28
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Alaska Airlines Strengthens Hawai'i Network With 737 Expansion
ALK adds daily 737-800 service on select Honolulu-Kahului flights, boosting inter-island capacity and premium amenities in Hawaii.
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants -- -- Robust target engagement of ALK5 observed with AGMB-447 in IPF patients -- -- Clinical Trial Application (CTA) for INSPIRIA Phase 2 study in IPF patients submitted; Company intends to initiate study before year-end -- Antwerp, Belgium, September 14, 2026 – Agomab Therapeutics NV (‘Agomab'), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the Phase 1 study of AGMB-447 in IPF patients. AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).1 The Phase 1 study of AGMB-447 is a three-part, double-blind, randomized, placebo-controlled single ascending dose (SAD; Part A; dose range: 1 mg QD (once daily) to 20 mg QD) and multiple ascending dose (MAD; Part B; dose range: 1 mg QD to 6 mg BID (twice daily)) study in healthy participants and multiple dose study in IPF patients (Part C; dose range: 4.5 mg BID to 6 mg BID).
Alaska Air Group (ALK) Declines More Than Market: Some Information for Investors
Alaska Air Group (ALK) concluded the recent trading session at $40.71, signifying a -1.09% move from its prior day's close.
Hsbc Holdings PLC Has $3.39 Million Stake in Alaska Air Group, Inc. $ALK
Hsbc Holdings PLC lowered its stake in Alaska Air Group, Inc. (NYSE: ALK) by 65.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,242 shares of the transportation company's stock after selling 122,254 shares during the quarter. Hsbc Holdings PLC
ALK to present at the Morgan Stanley Global Healthcare Conference in New York
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company's Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City taking place from 14 - 16 September 2026 on Monday, 14 September 2026, at 3.20 PM EDT.